Matthias Bartenstein

1.5k citations

16 papers · 661 indexed · h-index 8

Impact in

Hematology top 5%
- Acute Myeloid Leukemia Research
- Hematopoietic Stem Cell Transplantation
- Chronic Myeloid Leukemia Treatments
Cancer Research top 10%
- Cancer-related molecular mechanisms research

Papers in

Hematology 9
- Acute Myeloid Leukemia Research 6
- Hematopoietic Stem Cell Transplantation 4
- Chronic Myeloid Leukemia Treatments 3
Genetics 3
- Myeloproliferative Neoplasms: Diagnosis and Treatment 3

Co-authors: Amit Verma Yiting Yu H. Joachim Deeg Tushar D. Bhagat Andrea Pellagatti Jacqueline Boultwood Shanisha Gordon Sariat Ibrahim
Journals: Blood (5 papers)Hematology/Oncology Clinics of North America (1 paper)Journal of Clinical Oncology (1 paper)Cancer Research (1 paper)Archivum Immunologiae et Therapiae Experimentalis (1 paper)
Partner nations: United States United Kingdom China

In The Last Decade

Matthias Bartenstein

16 papers receiving 653 citations

Peers

Countries citing papers authored by Matthias Bartenstein

Since Specialization

Citations

This map shows the geographic impact of Matthias Bartenstein's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthias Bartenstein with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthias Bartenstein more than expected).

Fields of papers citing papers by Matthias Bartenstein

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matthias Bartenstein. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthias Bartenstein. The network helps show where Matthias Bartenstein may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Matthias Bartenstein, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Matthias Bartenstein Line = papers co-authored together Matthias Bartenstein links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work
1	Phase 2 trial of retifanlimab (anti–PD-1) in combination with INCAGN02385 (anti–LAG-3) and INCAGN02390 (anti–TIM-3) as first-line treatment in patients with PD-L1–positive recurrent/metastatic squamous cell carcinoma of the head and neck. Journal of Clinical Oncology ·Ezra E.W. Cohen, Christophe Le Tourneau, Richard Schaub, Matthias Bartenstein, Lulu Cheng, Lisa Licitra	2023	4
2	Myelodysplastic Syndrome and Sweet’s Syndrome Are Associated with a Mutation in Isocitrate Dehydrogenase 1 Anticancer Research ·Muhammad Maghfi, B.C. Vis, Patricia Raciti, Bijal Amin, Mark Jacobson, Dinesh Rakheja, Yongfa Zhu, Matthias Bartenstein, Changcheng Zhu, Swati Goel, Amit Verma, Aditi Shastri	2018	4
3	Efficacy of ALK5 inhibition in myelofibrosis JCI Insight ·庞崇, Matthias Bartenstein, Wanke Zhao, Wan‐Ting Ho, Ying Han, 藤村正哲, Adam W. Mailloux, Ling Zhang, Xuefeng Wang, Dwi Rahayu Nugraheni, Kith Pradhan, Franck Rapaport, Huaquan Wang, Zonghong Shao, Xiubao Ren, Ulrich Steidl, Ross L. Levine, Zhizhuang Joe Zhao, Amit Verma, Pearlie K. Epling‐Burnette	2017	34
4	The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes Journal of Clinical Investigation ·Bon Ham Yip, Violetta Steeples, Emmanouela Repapi, Richard N. Armstrong, Miriam Llorian, Swagata Roy, Jacqueline Shaw, Hamid Dolatshad, Stephen Taylor, Amit Verma, Matthias Bartenstein, Paresh Vyas, Nicholas C.P. Cross, Luca Malcovati, Mario Cazzola, Eva Hellström‐Lindberg, Seishi Ogawa, Christopher W. J. Smith, Andrea Pellagatti, Jacqueline Boultwood	2017	70
5	Bone marrow fibrosis in primary myelofibrosis: pathogenic mechanisms and the role of TGF-β. PubMed ·Archana M. Agarwal, Kerry Morrone, Matthias Bartenstein, Zhizhuang Joe Zhao, Amit Verma, Swati Goel	2016	55
6	IL8-CXCR2 pathway inhibition as a therapeutic strategy against MDS and AML stem cells Blood ·Carolina Schinke, Orsi Giricz, Weijuan Li, Aditi Shastri, Shanisha Gordon, Laura Barreyro, Tushar D. Bhagat, Sanchari Bhattacharyya, Nandini Ramachandra, Matthias Bartenstein, Andrea Pellagatti, Jacqueline Boultwood, Amittha Wickrema, Yiting Yu, Britta Will, Wei Sheng, Ulrich Steidl, Amit Verma	2015	145
7	ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts Oncotarget ·Simona Valletta, Hamid Dolatshad, Matthias Bartenstein, Bon Ham Yip, Erica Bello, Shanisha Gordon, Yiting Yu, Jacqueline Shaw, Swagata Roy, Laura Scifo, Anna Schuh, Andrea Pellagatti, Tudor A. Fulga, Amit Verma, Jacqueline Boultwood	2015	54
8	Preclinical Efficacy of TGF-Beta Receptor I Kinase Inhibitor, Galunisertib, in Myelofibrosis Blood ·庞崇, Matthias Bartenstein, Wanke Zhao, Wan‐Ting Ho, Ling Zhang, Franck Rapaport, Ross L. Levine, Zonghong Shao, Zhizhuang Joe Zhao, Amit Verma, Pearlie K. Epling‐Burnette	2015	5
9	Myelodysplastic Syndrome Marrow Stroma Shows Widespread Aberrant Hypermethylation That Is Abrogated By Treatment with Dnmt Inhibitors Blood ·Tushar D. Bhagat, Matthias Bartenstein, Yiting Yu, A. Mario Marcondes, Britta Will, Orsi Giricz, Davendra Sohal, Ioannis Mantzaris, Amittha Wickrema, Christine M. McMahon, Luisa Diana Handoyo, John M. Greally, Siddhartha Mukherjee, Ulrich Steidl, H. Joachim Deeg, Amit Verma	2014	2
10	Exome Sequencing of Familial MDS Reveals Novel Mutations and High Rates of False Positive Mutations in MLL3 Due to Pseudogene Effects Blood ·Timothy G. Bowler, Matthias Bartenstein, Kerry Morrone, Mersedeh Rohanizadegan, Rachel Kessel, AmitkumarBapuso Pandav, حسين نايلي, Orsi Giricz, Tushar D. Bhagat, Bartlomiej Przychodzen, Simrit Parmar, Jonathan Gill, Yiting Yu, Jaroslaw P. Maciejewski, Ulrich Steidl, Amit Verma	2014	2
11	Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett's Esophagus and Esophageal Adenocarcinoma Gastroenterology ·Wenjing Wu, Tushar D. Bhagat, Xue Yang, Jueping Song, Yulan Cheng, Rachana Agarwal, John Abraham, Sariat Ibrahim, Matthias Bartenstein, Zulfiqar Hussain, Masako Suzuki, Yiting Yu, Wei Chen, Charis Eng, John M. Greally, Amit Verma, Stephen J. Meltzer	2013	191
12	Abstract 1504: Pancreatic cancer associated fibroblasts are characterized by widespread epigenetic reprogramming that leads to aberrant expression of druggable target CXCR4. Cancer Research ·Tushar D. Bhagat, Yanique Rattigan, Brijesh Patel, Tatuli Dushuashvili, Yiting Yu, Davendra Sohal, Matthias Bartenstein, Orsi Giricz, Shanisha Gordon, Nishanth Vallumsetla, DAVID B. ELLER, Íria Caamaño-Franco, Paraic A. Kenny, John M. Greally, Debabrata Banerjee, Anirban Maitra, Amit Verma	2013	1
13	Preparing for DSM 5 – Assessment of personality pathology during psychoanalytic and psychiatric treatments Wiener klinische Wochenschrift ·Henriette Löffler‐Stastka, Matthias Bartenstein, Keerthi Somashekar	2011	2
14	Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome: Current Status Archivum Immunologiae et Therapiae Experimentalis ·H. Joachim Deeg, Matthias Bartenstein	2011	4
15	Inhibition of IL-32 activation by α-1 antitrypsin suppresses alloreactivity and increases survival in an allogeneic murine marrow transplantation model Blood ·A. Mario Marcondes, Xiang Li, Laura Tabellini, Matthias Bartenstein, F.A. Medetkhanov, George E. Sale, John A. Hansen, Charles A. Dinarello, H. Joachim Deeg	2011	61
16	Hematopoietic Stem Cell Transplantation for MDS Hematology/Oncology Clinics of North America ·Matthias Bartenstein, H. Joachim Deeg	2010	27

About Matthias Bartenstein

Matthias Bartenstein is a scholar working on Hematology, Genetics, Cancer Research, Rheumatology and Molecular Biology, having authored 16 papers that have together received 661 indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (6 papers), Hematopoietic Stem Cell Transplantation (4 papers), Chronic Myeloid Leukemia Treatments (3 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (3 papers), Eosinophilic Disorders and Syndromes (2 papers), Epigenetics and DNA Methylation (2 papers), Pancreatic and Hepatic Oncology Research (2 papers) and RNA modifications and cancer (2 papers). The work is most often cited by research in Hematology (252 citations), Cancer Research (196 citations), Genetics (125 citations), Molecular Biology (387 citations) and Immunology (118 citations). Matthias Bartenstein has collaborated with scholars based in United States, United Kingdom and China. Frequent co-authors include Amit Verma, Yiting Yu, H. Joachim Deeg, Tushar D. Bhagat, Andrea Pellagatti, Jacqueline Boultwood, Shanisha Gordon, Sariat Ibrahim, Masako Suzuki and Zhizhuang Joe Zhao. Their work appears in journals such as Blood, Hematology/Oncology Clinics of North America, Journal of Clinical Oncology, Cancer Research and Archivum Immunologiae et Therapiae Experimentalis.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact